Osteoporosis and Cardiovascular Disease Care in Systemic Lupus Erythematosus According to New Quality Indicators

Seminars in Arthritis and Rheumatism

Volumn 40, Issue 3, 2010, Pages 193-200

  Demas, Kristina L ^a   Keenan, Brendan T ^b   Solomon, Daniel H ^b   Yazdany, Jinoos ^c   Costenbader, Karen H ^b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood pressure; Bone mineral density; Calcium and vitamin D; Cardiovascular disease; Cholesterol; Management; Osteoporosis; Quality indicator; Risk factor; Screening; Systemic lupus erythematosus

Indexed keywords

ANABOLIC AGENT; CALCIUM; GLUCOCORTICOID; PREDNISONE; VITAMIN D;

ADULT; AGE DISTRIBUTION; ANAMNESIS; ARTICLE; BLOOD PRESSURE; BODY MASS; BONE DENSITOMETRY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DISEASE DURATION; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HEALTH CARE QUALITY; HEALTH INSURANCE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MEDICAL RECORD REVIEW; OSTEOPOROSIS; PATIENT CARE; PATIENT COUNSELING; PHYSICIAN; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RESISTANCE TRAINING; RISK FACTOR; SEX DIFFERENCE; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; VITAMIN SUPPLEMENTATION;

ADULT; BONE DENSITY; CARDIOVASCULAR DISEASES; FEMALE; GLUCOCORTICOIDS; HUMANS; LIPIDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MASS SCREENING; MIDDLE AGED; OSTEOPOROSIS; QUALITY ASSURANCE, HEALTH CARE; QUALITY INDICATORS, HEALTH CARE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 78649446093     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2010.01.001     Document Type: Article

References (31)

1. Yazdany J. Strategies for preventive care in systemic lupus erythematosus. J Musculoskel Med 2008, 25:316-320.
2. Yazdany J., MacLean C.H. Quality of care in the rheumatic diseases: current status and future directions. Curr Opin Rheumatol 2008, 20(2):159-166.
3. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001, 44(7):1496-1503. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
4. Solomon D.H., Morris C., Cheng H., Cabral D., Katz J.N., Finkelstein J.S., et al. Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc 2005, 80(2):194-202.
5. van Staa T.P., Leufkens H.G., Abenhaim L., Zhang B., Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000, 39(12):1383-1389.
6. Peat I.D., Healy S., Reid D.M., Ralston S.H. Steroid induced osteoporosis: an opportunity for prevention?. Ann Rheum Dis 1995, 54(1):66-68.
7. Urowitz M.B., Bookman A.A., Koehler B.E., Gordon D.A., Smythe H.A., Ogryzlo M.A. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976, 60(2):221-225.
8. Westerweel P.E., Luyten R.K., Koomans H.A., Derksen R.H., Verhaar M.C. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2007, 56(5):1384-1396.
9. Esdaile J.M., Abrahamowicz M., Grodzicky T., Li Y., Panaritis C., du Berger R., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44(10):2331-2337.
10. Svenungsson E., Jensen-Urstad K., Heimburger M., Silveira A., Hamsten A., de Faire U., et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001, 104(16):1887-1893.
11. Mosca M., Bombardieri S. Disease-specific quality indicators, guidelines, and outcome measures in systemic lupus erythematosus (SLE). Clin Exp Rheumatol 2007, 25(6 Suppl 47):107-113.
12. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum 1999, 42(9):1785-1796. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines.
13. Crossing the Quality Care Chasm: The IOM Health Care Quality Initiative July 20, 2006, In.
14. Yazdany J., Panopalis P., Gillis J.Z., Schmajuk G., Maclean C.H., Wofsy D., et al. A quality indicator set for systemic lupus erythematosus. Arthritis Rheum 2009, 61(3):370-377.
15. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40(9):1725.
16. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25(11):1271-1277.
17. Sangha O., Stucki G., Liang M.H., Fossel A.H., Katz J.N. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003, 49(2):156-163.
18. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
19. Manzi S., Meilahn E.N., Rairie J.E., Conte C.G., Medsger T.A., Jansen-McWilliams L., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997, 145(5):408-415.
20. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993, 269(23):3015-3023.
21. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. The Seventh Report of the Joint National Committee on Prevention. Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 2003, 289(19):2560-2572.
22. Djokanovic N., Klieger-Grossmann C., Koren G. Does treatment with bisphosphonates endanger the human pregnancy?. J Obstet Gynaecol Can 2008, 30(12):1146-1148.
23. Ginzler E.M., Aranow C. Prevention and treatment of adverse effects of corticosteroids in systemic lupus erythematosus. Bailliere Clin Rheumatol 1998, 12(3):495-510.
24. Bruce I.N., Gladman D.D., Urowitz M.B. Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study. Clin Exp Rheumatol 1998, 16(4):435-440.
25. Hallegua D.S., Wallace D.J. How accelerated atherosclerosis in SLE has changed our management of the disorder. Lupus 2000, 9(3):228-231.
26. Lockshin M.D., Salmon J.E., Roman M.J. Atherosclerosis and lupus: a work in progress. Arthritis Rheum 2001, 44(10):2215-2217.
27. Salmon J.E., Roman M.J. Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. Curr Opin Rheumatol 2001, 13(5):341-344.
28. Ahmann A.J. Guidelines and performance measures for diabetes. Am J Manag Care 2007, 13(Suppl 2):S41-S46.
29. (accessed January 2009). http://www.ama-assn.org/ama/pub/category/2946.html.
30. Watson K.E. The JUPITER trial: How will it change clinical practice?. Rev Cardiovasc Med 2009, 10(2):91-96.
31. Accessed December 15, 2009. http://www.rheumatology.org/RCR.